Botulinum toxin type B: A new injectable treatment for cervical dystonia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

Original languageEnglish (US)
Pages (from-to)2191-2199
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number12
DOIs
StatePublished - Dec 31 2001
Externally publishedYes

Fingerprint

Torticollis
Injections
Pain
Type A Botulinum Toxins
San Francisco
Spasm
Therapeutics
Smooth Muscle
rimabotulinumtoxinB

Keywords

  • Botulinum toxin
  • Cervical dystonia
  • Chemodenervation
  • Myobloc™
  • NeuroBloc®

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Botulinum toxin type B : A new injectable treatment for cervical dystonia. / Brashear, A.

In: Expert Opinion on Investigational Drugs, Vol. 10, No. 12, 31.12.2001, p. 2191-2199.

Research output: Contribution to journalArticle

@article{4c0346b52a744fe48a3edc48b0d2e0fe,
title = "Botulinum toxin type B: A new injectable treatment for cervical dystonia",
abstract = "Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.",
keywords = "Botulinum toxin, Cervical dystonia, Chemodenervation, Myobloc™, NeuroBloc{\circledR}",
author = "A. Brashear",
year = "2001",
month = "12",
day = "31",
doi = "10.1517/13543784.10.12.2191",
language = "English (US)",
volume = "10",
pages = "2191--2199",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
number = "12",

}

TY - JOUR

T1 - Botulinum toxin type B

T2 - A new injectable treatment for cervical dystonia

AU - Brashear, A.

PY - 2001/12/31

Y1 - 2001/12/31

N2 - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

AB - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

KW - Botulinum toxin

KW - Cervical dystonia

KW - Chemodenervation

KW - Myobloc™

KW - NeuroBloc®

UR - http://www.scopus.com/inward/record.url?scp=0035215847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035215847&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.12.2191

DO - 10.1517/13543784.10.12.2191

M3 - Article

C2 - 11772315

AN - SCOPUS:0035215847

VL - 10

SP - 2191

EP - 2199

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -